Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

ude statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that the clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
(Date:8/30/2014)... August 30, 2014 In today’s world, ... increasingly difficult to get. Snoring and sleep apnea (a ... breathing stops) robs people and their bed partners of ... Up to 45% of the population snores and 20 ... apnea. Of these, only 10% have been diagnosed and ...
(Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 McLeod's ... full service auto repair shop with strong ties to the ... Family is happy to announce they have been chosen by ... one pick for auto repair. , Tim McLeod’s father, ... Auto Service sixty years ago. Although his son, Tim runs ...
(Date:8/30/2014)... 2014 The SI Joint Evaluation and ... six muscle energy techniques. Michael P. Reiman PT, DPT, ... examination techniques for the SI Joint. This ... live course presentation with North American Seminars. ... Applying a differential diagnosis approach to a thorough examination ...
(Date:8/30/2014)... 30, 2014 What challenges exist in ... the latest trends, concerns, and considerations? Sports Conflict ... Pendleton recently spoke with Woody Wommack, Southeast Football Recruiting ... issues in football recruiting. Notably, Wommack spoke on ... changes that he thinks are coming as a result ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Response Systems,announced today two new contract awards, worth ... surge capacity for hospitals and,public health systems in ... Suffolk County, NY., The first contract, for ... the Idaho Central District Health Department. This,contract includes ...
... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading ... announced that it has entered into a definitive ... cash transaction valued at,approximately $26 million, subject to ... that brings quality healthcare to the,bedside through a ...
... rate of decline in lung function in children and adolescents ... Researchers found that patients with cystic fibrosis (CF) who took ... loss of lung function compared to those who did not ... two to seven years. , It is fairly evident ...
... Assay Developed Specifically for Resource-Limited ... Settings Joins Global Procurement Consortium, UPPSALA, Sweden, November ... today announced an agreement with the Clinton,Foundation HIV/AIDS Initiative ... immediately available to members of CHAI,s,Procurement Consortium at a ...
... Nov. 29 AstraZeneca (NYSE:,AZN) today announced that the ... an additional six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) ... to pediatric exclusivity being,granted by the FDA, the patent ... is currently approved in the US for the for ...
Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
... Laboratory is a comprehensive, ... manages specimen data from ... tracking to final cumulative ... is a multi-module system ...
... optimal speed, efficiency and results, without the ... Most importantly, EZLink meets strategic laboratory network ... in the same facility - without sacrificing ... paperless laboratory, the network can be linked ...
... Windows NT client server system that combines ... power and high-speed volume required to meet ... industry experts, LabNet is structured to make ... and effective as possible. Our system can ...
Medicine Products: